Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial
暂无分享,去创建一个
[1] P. Ridker,et al. Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2012, Circulation. Cardiovascular genetics.
[2] Jennifer G. Robinson,et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.
[3] Mark Woodward,et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies , 2012 .
[4] Audrey Y. Chu,et al. Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein , 2012, Circulation. Cardiovascular genetics.
[5] G. Owens,et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. , 2012, The Journal of clinical investigation.
[6] D. Rader. IL-1 and atherosclerosis: a murine twist to an evolving human story. , 2012, The Journal of clinical investigation.
[7] P. Libby,et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.
[8] S. Shoelson,et al. Type 2 diabetes as an inflammatory disease , 2011, Nature Reviews Immunology.
[9] Egil Lien,et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals , 2010, Nature.
[10] J. Danesh,et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.
[11] P. Hawkins,et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.
[12] Paul M Ridker,et al. Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.
[13] J. McMurray,et al. Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis , 2009, Circulation.
[14] N. Cook,et al. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. , 2009, JAMA.
[15] P. Ridker. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) , 2009, Journal of thrombosis and haemostasis : JTH.
[16] Børge G Nordestgaard,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.
[17] C. Dinarello,et al. Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.
[18] D. Fearon,et al. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. , 2008, Circulation.
[19] S. Malozowski,et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.
[20] Amy Shui,et al. Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial , 2006, Circulation.
[21] Peter Libby,et al. The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.
[22] H Tunstall-Pedoe,et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.
[23] Paul Schoenhagen,et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.
[24] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[25] P. Ridker,et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.
[26] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[27] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[28] C. Holt,et al. Interleukin-1β in Coronary Arteries of Patients With Ischemic Heart Disease , 1996 .
[29] P. Libby,et al. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. , 1995, The American journal of pathology.